➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Colorcon
AstraZeneca
Boehringer Ingelheim
Moodys

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

Litigation Details for The Medicines Company v. Mylan Inc. (N.D. Ill. 2011)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in The Medicines Company v. Mylan Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for The Medicines Company v. Mylan Inc. (N.D. Ill. 2011)

Date Filed Document No. Description Snippet Link To Document
2011-02-23 1 complaint Code, involving United States Patent Nos. 7,582,727 (“the ’727 patent”) (attached as Exhibit A hereto…1. This is an action for patent infringement arising under the patent laws of the United States, …727 and ’343 patents a bivalirudin drug product that infringes the ’727 and ’343 patents. …727 and ’343 patents a bivalirudin drug product that infringes the ’727 and ’343 patents. …the ’727 patent is an act of infringement by Mylan of one or more claims of the ’727 patent under 35 External link to document
2013-12-16 309 United States Patents Nos. 7,582,727 (the “’727 patent”) and 7,598,343 (the “’343 patent”). (R. 1, Compl…The ’727 patent is a product patent (see ’727 patent at col. 25-28), whereas the ’343 patent is a product-by-process…the ’727 patent is a pure product patent, not a product-by-process patent like the ’343 patent. (TMC Resp…U.S. Patent and Trademark Office issued the ’727 patent on September 1, 2009 and the ’343 patent on October…the ’343 patent but denies it with respect to the ‘747 patent. A. The ’343 Patent External link to document
2014-01-31 342 at trial that assumes that U.S. Patent No. 7,582,727 (“the ’727 patent”) requires the claimed Asp9 impurity…Exclude Expert Opinions That Assume Plaintiff's Patent Claims Require The ASP Impurity Maximums To Be …EXPERT OPINIONS THAT ASSUME PLAINTIFF’S PATENT CLAIMS REQUIRE THE ASP9 IMPURITY …term “consistently” is absent from the asserted patent claims and the parties both argued on summary judgment…judgment that the term should not be read into the patent claims. The Court relied upon that concurrence External link to document
2014-03-25 406 infringement of United States Patent No. 7,582,727 (the “’727 patent”),1 a product patent. In advance of trial…covered by multiple patents, including the ‘727 patent, the ‘343 patent and U.S. Patent No. 5,196,404. Moreover… arises out of a patent infringement case involving the ‘727 Patent. The ‘727 patent “relates to a compounding…judgment motion as to United States Patent No. 7,598,343 (the “’343 patent”). (R. 309.) …asserted that the ‘727 patent is obvious and thus invalid under 35 U.S.C. § 103. “A patent may not issue ‘if External link to document
2014-03-27 408 of a patent infringement case involving U.S. Patent No. 7,582,727 (R. 358-1, “the ‘727 Patent”) The …judgment of non-infringement of the other patent-in-suit (U.S. Patent No. 7,598,343), and also granted Defendants…The ‘727 patent “relates to a compounding process for preparing a pharmaceutical batch(es) of a drug product…bivalirudin as an active ingredient.” (Id., ‘727 patent at col. 2 ll. 29-32) Bivalirudin is the active …Angiomax® since 2001. Before expiration of the patents-in-suit, Mylan submitted Abbreviated New Drug Application External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
McKesson
Boehringer Ingelheim
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.